Insmed Gains US Approval of Lung Disease Drug Forecast to Be Blockbuster

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.

FDA Approval of First-in-Class BRINSUPRI Offers New Hope for Hundreds of Thousands with Chronic Lung Disease

The U.S. Food and Drug Administration (FDA) has approved Insmed’s oral drug BRINSUPRI (brensocatib) as the first treatment for non-cystic fibrosis bronchiectasis (NCFB) in patients … FDA Approval of First-in-Class BRINSUPRI Offers New Hope for Hundreds of Thousands with Chronic Lung Disease Read More » The post FDA Approval of First-in-Class BRINSUPRI Offers New Hope for Hundreds of Thousands with Chronic Lung Disease first appeared on GeneOnlin…

Serious Chronic Lung Disease Gets First FDA-Approved Drug

(MedPage Today) — The FDA approved oral brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis in adults and kids 12 years and up, drugmaker Insmed announced on Tuesday. A first-in-class reversible dipeptidyl peptidase… Source link : https://www.medpagetoday.com/pulmonology/generalpulmonary/116965 Author : Publish date : 2025-08-12 21:10:00 Copyright for syndicated content belongs to the linked Source. The post Ser…

FDA Approves First Treatment for Chronic Inflammatory Lung Condition

Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis (NCFB).

FDA approves brensocatib to treat adolescents with non-cystic fibrosis bronchiectasis

Brensocatib was granted FDA priority review in February 2025 for the small molecule, oral, reversible inhibitor.

FDA Makes History: First-Ever Treatment for 500,000 Non-Cystic Fibrosis Bronchiectasis Patients Gets Approval

Breakthrough BRINSUPRI shows 21% reduction in lung disease flare-ups. First-ever approved therapy for chronic bronchiectasis patients. Learn full benefits.